- Ventas continues to predict normalized FFO per share to range from $3.07 to $3.18, with an estimated average of $3.13.
- The company foresees a rise in SHOP same-store cash NOI (Net Operating Income) of between 10.0% to 15.0%.
- This growth is primarily driven by the U.S, which is expected to experience mid-to-high teens growth.
- There is an expectation of accelerating year-on-year same-store cash NOI and Normalized FFO growth within the year.
- Strong demand is bolstering an acceleration in average occupancy growth on a year-over-year basis.
- This growth in occupancy is forecasted to continue throughout 2024.
- Investor sentiment is positive, with 15 buys, 6 holds, and 0 sells.
A look at Ventas Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Ventas, Inc. is a real estate investment trust that owns and operates various healthcare properties in the United States and Canada. According to the Smartkarma Smart Scores, the company has an overall positive outlook with a score of 3 out of 5 for value, 4 for dividend, 3 for growth, 2 for resilience, and 3 for momentum. This indicates that Ventas Inc. is a stable and reliable company with a strong potential for growth.
The company’s high dividend score suggests that it is committed to providing steady returns to its investors. With a focus on healthcare properties, Ventas Inc. is well-positioned for growth in the long-term, as the demand for healthcare services continues to increase. However, its lower resilience score may indicate potential risks in the future. Overall, Ventas Inc. shows promise for investors looking for a stable and potentially profitable long-term investment in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
